BeOne Medicines financials
$365.27−0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $5.34B |
| Gross profit | $4.67B |
| Gross margin | 87.5% |
| Operating income | $447.1M |
| Net income | $286.9M |
| Net margin | 5.4% |
| Diluted EPS | $0.19 |
| EBITDA | $588.8M |
| Operating cash flow | $1.13B |
| Free cash flow | $881.0M |
| Diluted shares | 1,474.8M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $4.55B |
| Short-term investments | $0.00 |
| Total debt | $1.02B |
| Total assets | $8.19B |
| Total liabilities | $3.83B |
| Shareholders' equity | $4.36B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology